Table 1

Association between blood amyloid and brain amyloid pathology

ResultCohort detailsTechnology typeAUC
(Aβ+ vs Aβ−)
Ref
↓ Plasma Aβ42 in Aβ+ group vs Aβ− group*22 Aβ−, 40 Aβ+ (PET)IP-MS0.81 28
Cohort 1 (NCGG): 71 Aβ−, 50 Aβ+ (PET)
Cohort 2 (AIBL): 115 Aβ−, 137 Aβ+
(PET)
IP-MSCohort 1: 0.87 (0.91†)
Cohort 2: 0.72 (0.80†)
Cohort 1 and 2: 0.79
29
359 Aβ−, 82 Aβ+ (PET)IP-MS0.74 (0.79‡) 30
46 Aβ−, 23 Aβ+ (PET)Simoa0.66 25
191 Aβ−, 57 Aβ+ (CSF)Simoa0.66 25
359 Aβ−, 82 Aβ+ (PET)Simoa0.59 (0.71‡) 30
45 Aβ−, 23 Aβ+ (PET)Simoa0.78 41
474 Aβ−, 368 Aβ+ (CSF)Elecsys0.71 35
↓ Plasma Aβ42 in Aβ+ CU, Aβ+ SCD, Aβ+ MCI, Aβ+ AD vs Aβ− CU, Aβ− MCICU (200 Aβ−, 74 Aβ+), 60 Aβ+ SCD, 121 Aβ+ MCI, 53 Aβ+ AD
(CSF)
Simoa 18
CU (366 Aβ−, 147 Aβ+), MCI (108 Aβ−, 157 Aβ+), 64 Aβ+ AD
(CSF)
Elecsys 35
↑ Plasma exosome bound Aβ42 in Aβ+ group vs Aβ− group*45 Aβ−, 23 Aβ+ (PET)APEX0.99 40 and 41
No sig. difference in plasma Aβ42 between Aβ+ vs Aβ− groups*10 Aβ−, 10 Aβ+ (PET)MSD 37
↓ Plasma Aβ42/Aβ40 ratio in Aβ+ group vs Aβ− group*22 Aβ−, 40 Aβ+ (PET)IP-MS0.80 28
23 Aβ−, 18 Aβ+ (PET or CSF)IP-MS0.89 31
115 Aβ−, 43 Aβ+ (PET)IP-MS0.88 (0.94§) 22
359 Aβ−, 82 Aβ+ (PET)IP-MS0.82 (0.84‡) 30
161 Aβ− and 38 Aβ+ (PET)Simoa0.79 (0.81§) 23
191 Aβ−, 57 Aβ+ (CSF)Simoa0.77 (0.83§) 25
359 Aβ−, 82 Aβ+ (PET)Simoa0.62 (0.73‡) 30
45 Aβ−, 23 Aβ+ (PET)Simoa0.82 41
474 Aβ−, 368 Aβ+ (CSF)Elecsys0.77 (0.80¶, 0.85**) 35
161 Aβ− and 38 Aβ+ (PET)ELISA0.78 (0.78§) 23
↓ Plasma Aβ42/Aβ40 ratio in Aβ+ CU, Aβ+ SCD, Aβ+ MCI, Aβ+ AD vs Aβ− CU, Aβ− MCICU (200 Aβ−, 74 Aβ+), 60 Aβ+ SCD, 121 Aβ+ MCI, 53 Aβ+ AD
(CSF)
Simoa 18
CU (366 Aβ−, 147 Aβ+), MCI (108 Aβ−, 157 Aβ+), 64 Aβ+ AD
(CSF)
Elecsys 35
No sig. difference in plasma Aβ42/Aβ40 ratio between Aβ+ vs Aβ− groups*46 Aβ−, 23 Aβ+ (PET)Simoa0.68 (0.79§) 25
32 Aβ−, 8 Aβ+ (PET)Simoa 87
10 Aβ−, 10 Aβ+ (PET)MSD 37
↑ Plasma Aβ40/Aβ42 ratio in Aβ+ group vs Aβ− group*Cohort 1 (NCGG): 71 Aβ−, 50 Aβ+ (PET)
Cohort 2 (AIBL): 115 Aβ−, 137 Aβ+ (PET)
IP-MSCohort 1: 0.97 (0.98†)
Cohort 2: 0.84 (0.85†)
Cohort 1 and 2: 0.89
29
↑ Plasma APP669-711/Aβ42 ratio in Aβ+ group vs Aβ− group*22 Aβ−, 40 Aβ+ (PET)IP-MS0.97 28
Cohort 1: 71 Aβ−, 50 Aβ+ (PET)
Cohort 2: 115 Aβ−, 137 Aβ+ (PET)
IP-MSCohort 1: 0.92 (0.93†)
Cohort 2: 0.83 (0.85†)
Cohort 1 and 2: 0.86
29
↑ Plasma composite biomarker in Aβ+ group vs Aβ− group*
(composite=average of the normalised values of APP669-711/Aβ42 ratio and Aβ40/Aβ42 ratio)
Cohort 1: 71 Aβ−, 50 Aβ+ (PET)
Cohort 2: 115 Aβ−, 137 Aβ+ (PET)
IP-MSCohort 1: 0.97 (0.97†)
Cohort 2: 0.88 (0.89†)
Cohort 1 and 2: 0.91
29
359 Aβ−, 82 Aβ+ (PET)IP-MS0.82 (0.84‡) 30
  • *For comparison between Aβ+ and Aβ− groups, participants of different clinical diagnoses are included.

  • †AUC after adjusted for age, gender, Apolipoprotein E genotype (APOE), clinical category.

  • ‡AUC after adjusted for age, gender, APOE.

  • §AUC after adjusted for age, APOE.

  • ¶AUC for inclusion of plasma Aβ42 and Aβ40 as separate predictors in logistic regression.

  • **AUC for inclusion of plasma Aβ42, Aβ40 and APOE as separate predictors in logistic regression.

  • ††AUC after adjusted for age, gender.

  • Aβ, amyloid-β; AD, Alzheimer’s disease; AIBL, Australian Imaging, Biomarker and Lifestyle Study of Ageing; AUC, area under the receiver operating characteristic curve; CSF, cerebrospinal fluid; CU, Cognitively unimpaired; IP-MS, immunoprecipitation-mass spectrometry; MCI, mild cognitive impairment; MSD, Meso Scale Discovery; NCGG, Japanese National Center for Geriatrics and Gerontology; PET, positron emission tomography; SCD, Subjective cognitive decline ; Simoa, single molecule array.